In Silico Studies of Potent Tyrosine Kinase Inhibitors: Molecular Docking and Pharmacophore Modeling Approaches

Description

Evangelos Mavridis, Eleni Pontiki, and Dimitra Hadjipavlou-Litina use computer methods, in a 2026 study, to assess small molecules as blockers of tyrosine kinases. Those enzymes are switches in cell growth signals, and blocking them is a major cancer drug strategy. Reusing known compounds for new targets can save time and money over starting from scratch.

Six compounds from the team's earlier research were put through similarity checks, docking simulations, and shape based pharmacophore models. Database searches added more candidates for comparison. Four of the six compounds showed signs of acting on several kinase targets at once. Those targets include receptors tied to blood vessel growth, cell growth, and breast cancer. The models were then used to screen for further candidates. The study is fully in silico, so its hits await lab testing to confirm real activity.

Catalog record

Source: https://europepmc.org/articles/PMC13209961